CalciMedica (CALC) Competitors $3.51 -0.19 (-5.14%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends CALC vs. CARA, SKYE, ACTU, SGMT, LFVN, BDTX, GALT, IPHA, VTYX, and TNYAShould you be buying CalciMedica stock or one of its competitors? The main competitors of CalciMedica include Cara Therapeutics (CARA), Skye Bioscience (SKYE), Actuate Therapeutics (ACTU), Sagimet Biosciences (SGMT), LifeVantage (LFVN), Black Diamond Therapeutics (BDTX), Galectin Therapeutics (GALT), Innate Pharma (IPHA), Ventyx Biosciences (VTYX), and Tenaya Therapeutics (TNYA). These companies are all part of the "pharmaceutical products" industry. CalciMedica vs. Cara Therapeutics Skye Bioscience Actuate Therapeutics Sagimet Biosciences LifeVantage Black Diamond Therapeutics Galectin Therapeutics Innate Pharma Ventyx Biosciences Tenaya Therapeutics Cara Therapeutics (NASDAQ:CARA) and CalciMedica (NASDAQ:CALC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends, media sentiment, community ranking and profitability. Which has more volatility and risk, CARA or CALC? Cara Therapeutics has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500. Comparatively, CalciMedica has a beta of 1.3, suggesting that its share price is 30% more volatile than the S&P 500. Do insiders & institutionals believe in CARA or CALC? 44.7% of Cara Therapeutics shares are owned by institutional investors. 3.1% of Cara Therapeutics shares are owned by insiders. Comparatively, 41.5% of CalciMedica shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has better valuation & earnings, CARA or CALC? CalciMedica has lower revenue, but higher earnings than Cara Therapeutics. CalciMedica is trading at a lower price-to-earnings ratio than Cara Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCara Therapeutics$20.97M0.78-$118.51M-$2.04-0.15CalciMedicaN/AN/A-$34.36M-$1.40-2.51 Does the MarketBeat Community believe in CARA or CALC? Cara Therapeutics received 654 more outperform votes than CalciMedica when rated by MarketBeat users. However, 92.86% of users gave CalciMedica an outperform vote while only 73.22% of users gave Cara Therapeutics an outperform vote. CompanyUnderperformOutperformCara TherapeuticsOutperform Votes66773.22% Underperform Votes24426.78% CalciMedicaOutperform Votes1392.86% Underperform Votes17.14% Do analysts prefer CARA or CALC? Cara Therapeutics presently has a consensus target price of $2.32, suggesting a potential upside of 681.14%. CalciMedica has a consensus target price of $20.67, suggesting a potential upside of 488.79%. Given Cara Therapeutics' higher probable upside, equities analysts clearly believe Cara Therapeutics is more favorable than CalciMedica.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cara Therapeutics 0 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00CalciMedica 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer CARA or CALC? In the previous week, CalciMedica had 9 more articles in the media than Cara Therapeutics. MarketBeat recorded 10 mentions for CalciMedica and 1 mentions for Cara Therapeutics. CalciMedica's average media sentiment score of 0.29 beat Cara Therapeutics' score of 0.00 indicating that CalciMedica is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cara Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CalciMedica 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Is CARA or CALC more profitable? CalciMedica has a net margin of 0.00% compared to Cara Therapeutics' net margin of -1,010.20%. CalciMedica's return on equity of -146.47% beat Cara Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cara Therapeutics-1,010.20% -241.31% -110.04% CalciMedica N/A -146.47%-98.78% SummaryCalciMedica beats Cara Therapeutics on 12 of the 17 factors compared between the two stocks. Ad InvestorPlaceWhy Buffett, Bezos, & Congress Are Piling Into This One SectorWhy are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Congress shifting their stocks in a frenzy? And why are they all piling into ONE unique corner of the market…Click here for the details Get CalciMedica News Delivered to You Automatically Sign up to receive the latest news and ratings for CALC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CALC vs. The Competition Export to ExcelMetricCalciMedicaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$37.73M$7.42B$5.50B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E Ratio-2.519.84114.8315.12Price / SalesN/A401.431,497.30100.87Price / CashN/A47.3939.6834.09Price / Book2.475.324.665.02Net Income-$34.36M$153.56M$119.06M$225.46M7 Day Performance-12.80%0.13%0.80%0.37%1 Month Performance-17.80%15.23%5.65%3.57%1 Year Performance45.64%41.14%36.75%29.43% CalciMedica Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CALCCalciMedica3.4648 of 5 stars$3.51-5.1%$20.67+488.8%+63.3%$37.73MN/A-2.5130Insider BuyingShort Interest ↓News CoverageHigh Trading VolumeCARACara Therapeutics4.1414 of 5 stars$0.31+6.9%$2.32+647.4%-75.5%$16.97M$11.00M-0.1555News CoverageHigh Trading VolumeSKYESkye Bioscience1.6381 of 5 stars$5.24+2.9%$18.67+256.2%+247.5%$158.97MN/A0.0011Gap UpACTUActuate TherapeuticsN/A$8.13-5.0%N/AN/A$158.80MN/A54.2010News CoverageGap UpSGMTSagimet Biosciences2.4691 of 5 stars$5.15-3.6%$24.00+366.0%+50.1%$156.52M$2M0.008Analyst ForecastNews CoverageLFVNLifeVantage3.2124 of 5 stars$12.22-5.5%N/A+72.0%$155.21M$200.16M53.13260Earnings ReportDividend AnnouncementShort Interest ↑News CoverageBDTXBlack Diamond Therapeutics2.2329 of 5 stars$2.74-4.5%$15.50+465.7%+56.6%$154.82MN/A-1.8390Upcoming EarningsShort Interest ↑GALTGalectin Therapeutics1.6885 of 5 stars$2.47-2.0%$11.00+345.3%+24.4%$153.83MN/A-3.139Positive NewsIPHAInnate Pharma3.3451 of 5 stars$1.89+3.3%$11.50+508.1%-13.6%$153.11M$24.85M0.00220Gap UpVTYXVentyx Biosciences2.7863 of 5 stars$2.16-2.3%$8.29+283.6%-85.1%$152.65MN/A-0.7873Positive NewsTNYATenaya Therapeutics3.1316 of 5 stars$1.92-6.3%$15.25+694.3%+4.9%$151.47MN/A-1.25110Gap Up Related Companies and Tools Related Companies Cara Therapeutics Alternatives Skye Bioscience Alternatives Actuate Therapeutics Alternatives Sagimet Biosciences Alternatives LifeVantage Alternatives Black Diamond Therapeutics Alternatives Galectin Therapeutics Alternatives Innate Pharma Alternatives Ventyx Biosciences Alternatives Tenaya Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CALC) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CalciMedica, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CalciMedica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
